Compare RAMP & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAMP | RCKT |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 394.2M |
| IPO Year | 1994 | 2014 |
| Metric | RAMP | RCKT |
|---|---|---|
| Price | $37.92 | $3.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $35.60 | $29.73 |
| AVG Volume (30 Days) | 808.8K | ★ 1.4M |
| Earning Date | 05-20-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22500.00 | 26.37 |
| EPS | 0.28 | ★ 0.66 |
| Revenue | ★ $812,940,000.00 | N/A |
| Revenue This Year | $11.18 | N/A |
| Revenue Next Year | $9.09 | $64.28 |
| P/E Ratio | $135.04 | ★ $5.18 |
| Revenue Growth | ★ 9.03 | N/A |
| 52 Week Low | $21.71 | $2.53 |
| 52 Week High | $38.23 | $5.45 |
| Indicator | RAMP | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 60.13 | 46.97 |
| Support Level | $37.65 | $3.32 |
| Resistance Level | $37.91 | $3.37 |
| Average True Range (ATR) | 0.14 | 0.19 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 68.42 | 47.80 |
LiveRamp Holdings Inc is a technology company that empowers marketers and media owners to deliver and measure marketing performance everywhere it matters. Its data collaboration network seamlessly unites data across advertisers, ad tech platforms, publishers, data providers, and commerce media networks, unlocking insights that deliver transformational consumer experiences and drive measurable business outcomes. The group's platform is engineered for AI agent accessibility, facilitating autonomous data collaboration between the specialized AI agents utilized by customers and partners and the networked platform. It generates the geographic revenue from the United States, followed by Europe, Asia-Pacific ("APAC"), and Other.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.